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Chimeric antigen receptor T cells can induce impressive response 
rates in patients with refractory B cell malignancies. Adoptive transfer 
of tumor infiltrating lymphocytes or T cell receptor-engineered 
T cells are other promising treatment modalities currently in clinical 
development. Requirements for clinical trial design for T cell-based 
cancer immunotherapy significantly differ from established criteria 
for small-molecule or antibody-based anticancer drugs. Here, we 
highlight important differences regarding preclinical development, 
trial design, and reporting of clinical trials.
The development of cellular cancer immu-
notherapies is spurred by the success of an-
ti-CD19 chimeric antigen receptor (CAR) 
T cells in B cell malignancies. These syn-
thetic receptors, constituted by the antigen 
binding domain of an antibody fused to the 
T-cell receptor stimulatory and costimula-
tory domains, recapitulate a full-fledged T 
cell activation.1 CAR T cells specific for 
CD19 have induced unprecedented re-
sponse rates in refractory B cell-acute lym-
phatic leukemia and in diffuse large B cell 
lymphoma leading to approval by the US 
Food and Drug Administration (FDA) and 
the European Medicines Agency (EMA). 
Although CAR T cells are investigated in 
a large variety of hematological and solid 
malignancies, the adoptive transfer of 
tumor infiltrating lymphocytes—which has 
been pursued for many years—or of T-cell 
receptor-engineered T cells are other prom-
ising treatment strategies (Figure 1).2 The 
specificities for the clinical development of 
immune-oncology (IO) agents in general 
have been discussed previously.3 Universal 
challenges for clinical IO trials include a 
toxicity profile that is significantly different 
from conventional cytostatic cancer drugs 
regarding kinetics and dose- dependency, 
the need for new ways of response assess-
ment, and ways to identify optimal com-
bination partners.3 Early clinical trials for 
antibody-based IO agents mainly inves-
tigate one to two new agents alone or in 
combination with the established standard 
(chemo)-therapy. Cellular cancer immuno-
therapy trials are more complex. In general, 
infusion of the cellular product is preceded 
by a lymphodepleting chemotherapy with 
its own potential for serious adverse events 
and is followed by the (per-protocol) appli-
cation of rescue medication (e.g., steroids 
and tocilizumab) for cytokine release syn-
drome and other immune-related adverse 
events in a large proportion of patients 
(Figure 1). Additionally, the genetic engi-
neering (e.g., generation of fourth genera-
tion CARs) and the manufacturing process 
(e.g., CD4 to CD8 ratio and activation 
protocols of T cells) of the cellular product 
itself often vary between different trials, 
which might have significant effects on effi-
cacy and safety of the cellular product.
Safety considerations for early cellular 
cancer immunotherapy trials
For conventional cytotoxic drugs, one tenth 
of the lethal dose to 10% of mice has been 
established as starting dose for first-in-hu-
man clinical trials. This starting dose might 
be further reduced if toxicity  occurs below 
this threshold in nonrodent animals.4 For 
molecular-targeted agents, such a clear con-
vention is missing. The current practice of 
establishing the starting dose by a variety of 
toxicological parameters from experiments 
in at least one rodent and one nonrodent 
animal model seems to be safe.4 Minimal 
anticipated biological effect level was pro-
posed as a starting dose for first-in-human 
studies with monoclonal antibodies by the 
EMA following the severe anti-CD28 anti-
body TGN1412 incident in 2007. Minimal 
anticipated biological effect level is not only 
based on in vivo but also on the available in 
vitro information.5
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For cellular immunotherapy, no rec-
ommendation on dose selection exists. 
Importantly, toxicity not only depends 
on the number of infused cells but is also 
influenced by the conditioning regimen 
and tumor burden of individual patients.3 
Moreover, no appropriate animal model 
exists to predict on-target but off-tumor or 
off-target effects of T cell-based immuno-
therapy, resulting in several fatal incidents 
in early clinical trials for T cell-based ther-
apies in colorectal cancer, melanoma, and 
myeloma.6 Risk mitigation strategies, such 
as split-dosing or application of a test dose, 
are also difficult to apply given the kinetics 
of T cell activation and expansion in  vivo 
that usually climax around day 7. This 
was exemplified by a trial investigating the 
use of an affinity-enhanced T cell recep-
tor (TCR) against HLA-A*01–restricted 
MAGE-A3. The first two treated patients 
within this clinical trial died from cardiac 
shock, secondary to cross-reactivity of the 
engineered TCR against an unrelated pep-
tide on cardiomyocytes. The use of a split 
dose in one of the cases was not able to pre-
vent this fatal event.6
A vigorous preclinical safety evalua-
tion, including in vitro screening of human 
cells,  tissues, and cellular models, as well as 
in silico-based approaches to exclude potential 
cross-reactivity, is therefore highly important. 
In addition, rather than focusing solely on a 
potentially safe starting dose, novel safety 
measures might be more important depend-
ing on the CAR or TCR construct under in-
vestigation. Safety measures currently under 
clinical investigation include the use of in-
ducible suicide genes that can be pharmaco-
logically activated upon appearance of higher 
grade toxicities (e.g., NCT02107963) or use 
of adapter CAR T cells as potential dose con-
trol of CAR T cell effector function.7 Other 
potential strategies include the clinical eval-
uation of new pharmacological rescue med-
ications. One potential candidate could be 
dasatinib, which has recently been shown to 
potently and reversibly suppress CAR T cell 
cytotoxicity, cytokine secretion, and prolifer-
ation in NSG mice.8
Trial design and efficacy evaluation
In conventional clinical development pro-
grams, phase I trials were mainly designed 
to establish safety, feasibility, and the rec-
ommended phase II dose. (Preliminary) 
efficacy was then evaluated in the subse-
quent phase II trial. As discussed above, 
side effects from CAR T cells or TCR-
engineered T cells are often serious and 
might lead to fatal incidents. Decision 
on whether or not to further pursue the 
clinical development of such potentially 
harmful treatments highly depends on 
the relation between observed efficacy 
and toxicity. The classical phase I 3  +  3 
dose escalation design is not suitable to 
continuously reassess this relation. More 
appropriate are adaptive, seamless phase 
I/II trials with multiple cohorts and con-
stant reassessment of the ratio between 
efficacy and toxicity.9 Translating results 
from such trials to the general patient pop-
ulation is often difficult: expedited EMA 
(PRIority Medicines (PRIME)) and FDA 
(FDA breakthrough designation) approval 
for axicabtagene ciloleucel and tisagenlec-
leucel was based on data from single-arm 
phase I/II (ZUMA-1) or single-arm phase 
II trials (ELIANA and JULIET). As seen 
for many expedited approvals, efficacy was 
assessed by overall response rate (ORR) ob-
served in treated patients without mature 
data on more patient-relevant end points, 
such as progression-free survival or overall 
survival. It is important to acknowledge 
the shortcomings of such trial designs in 
comparison to conventional drug approv-
als based on large phase III studies: First, 
because of the lack of a control arm, it re-
mains unclear how much of the antitumor 
effect can be attributed to the conditioning 
chemotherapy and how much to the actual 
CAR T cell therapy. Especially, if the pri-
mary end point is ORR determined shortly 
after therapy (e.g., 3 months after infusion 
for the ELIANA trial). Furthermore, in 
the trials mentioned above, ORR is only 
reported for transfused patients. When 
interpreting these data, it has to be taken 
into account that a significant proportion 
of patients enrolled in those three clinical 
trials did not receive the planned CAR T 
cell infusion, for different reasons. In the 
JULIET trial, only 111 of 165 enrolled pa-
tients (67%) received a CAR T cell infusion 
compared with 101 of 111 in the ZUMA-1 
trial (91%). Most frequent reasons for 
study dropout before CAR T cell infusion 
were disease progression, infections, other 
Figure 1 Adoptive T cell therapy. ACT, Adoptive T cell therapy; CAR, chimeric antigen receptor; 
IL-2, interleukin; IO, immune-oncology; TCR, T-cell receptor; TIL, tumor infiltrating lymphocyte. 
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adverse events, or death. Manufacturing 
problems only accounted for a small num-
ber of dropouts. Interestingly, the use of 
bridging therapies during the time inter-
val for manufacturing and shipping of the 
final CAR T cell product was permitted 
in the JULIET but not in the ZUMA-1 
trial. It could be speculated that this led 
to a difference in a priori patient selection 
(i.e., investigators might have been more 
reluctant to include patients with an ag-
gressive tumor biology and a high risk for 
rapid progression to the ZUMA-1 trial). 
The observational end point “enrollment 
but no treatment” might be an important 
clinical indicator of real-world shortcom-
ings of CAR T cell therapies. Future trials 
will need to incorporate careful scrutiny 
as to why a significant proportion of pa-
tients might not get treatment in spite 
of enrollment. It might be adequate for 
early trials that the logistics are not yet 
mature and efficient enough leading to a 
longer turnaround time with subsequent 
dropout (e.g., due to disease progression 
during waiting time). On the other hand, 
a high dropout rate even with optimized 
logistics in a highly selected clinical trial 
population might herald major problems 
in translating the results to a wider patient 
population.
Evidence development from cellular 
cancer immunotherapy trials
As mentioned above, protocols for cellular 
cancer immunotherapy are complex and 
can be modified in many ways. Currently, 
there are almost 600 registered clinical 
trials on CAR T cell therapy. About 50% 
of these trials focus on only three disease 
entities: acute lymphoblastic leukemia, B 
cell lymphoma, and multiple myeloma.2 
Given the fact that cellular immunother-
apy trials can only be performed at highly 
specialized centers, many trials compete 
for a small number of patients. Moreover, 
treatment protocols and the cellular prod-
uct itself largely differ in many cases. 
Together with the fact that many of the re-
ported trials are small single-arm phase II 
studies, this significantly restrains sound 
evidence development for cellular cancer 
immunotherapy. Possible improvements 
that have been proposed previously include 
standardized reporting schemes for clini-
cal trials, creation of central repositories to 
report treatment and outcome in detail, as 
well as innovative models to summarize or 
“map” the currently available evidence in 
an efficient and rapid way.10
In addition, many of the trials on cellu-
lar cancer immunotherapy are performed 
as investigator-initiated clinical trials. It 
would be highly desirable to organize and 
structure these individual research efforts 
in clinical study groups to advance ev-
idence development for cellular cancer 
immunotherapy in a more efficient way. 
One positive example is the European 
“EuroCARTForce” initiative that aims to 
jointly harmonize and improve manage-
ment of adverse effects from T cell-based 
immunotherapy.
In summary, with T cell-based therapy 
having entered the clinical realm, immense 
efforts are being made to broaden its appli-
cation and scope. With a growing number 
of trials but limited evidence for ideal and 
comparable trial design, there is a need for 
both investigators and sponsors to harmo-
nize means. Aside from the trials them-
selves, there is also a critical need to render 
comparable the preclinical setting on prod-
uct generation, efficacy, and safety testing 
as well as the regimens for precondition-
ing of patients. Together, these endeavors 
might culminate in faster development and 
prioritization of cellular products to the 
benefit of patients with cancer.
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